医疗器械ETF永赢(159883)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
-930,328,343.64 |
-152,237,692.59 |
-10,491,083.26 |
-274,348,130.11 |
| 利息合计 |
41,593.81 |
40,365.14 |
8,504.45 |
2,441,107.71 |
| 其中:存款利息收入 |
41,593.81 |
40,365.14 |
8,504.45 |
34,009.65 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-317,738,911.72 |
-86,939,079.89 |
-75,129,745.12 |
-263,459,092.45 |
| 其中:股票投资收益 |
-357,978,649.64 |
-122,981,443.46 |
-92,048,098.45 |
-288,376,428.33 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
40,239,737.92 |
36,042,363.57 |
16,918,353.33 |
24,917,335.88 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-618,597,805.55 |
-71,826,547.60 |
64,299,454.68 |
-17,236,448.02 |
| 其他收入 |
5,966,779.82 |
6,487,569.76 |
330,702.73 |
3,906,302.65 |
| 费用 |
16,309,502.40 |
17,300,709.59 |
5,109,257.48 |
10,686,758.97 |
| 管理人报酬 |
13,494,728.51 |
14,235,653.74 |
4,173,501.60 |
8,730,784.56 |
| 基金托管费 |
2,698,945.70 |
2,847,130.78 |
834,700.36 |
1,746,156.98 |
| 销售服务费 |
- |
- |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
115,828.19 |
217,925.07 |
101,055.52 |
201,151.52 |
| 利润总额 |
-946,637,846.04 |
-169,538,402.18 |
-15,600,340.74 |
-285,034,889.08 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年